Biotech Startups

Watershed provides a computational platform for biological research, combining analytics, secure supercomputing resources, and bioinformatics expertise to accelerate drug discovery and scientific analysis across genomics, proteomics, and imaging data.

1 investor

WaveClear is a personalized mindset and skills training tool for League of Legends players that tracks focus and in-game performance in real-time (without hardware) to help gamers improve consistency, ignore toxicity, and rank up. It combines wellness research and pro-coaching methods to train mindset, mechanics, and goal setting during gameplay.

1 investor

Wavefront develops quantitative 3D cell imaging technology for biomedical researchers to accelerate discoveries in cell science and healthcare applications.

1 investor

Paradoxx develops hair care products formulated with natural ingredients and proprietary technology to promote scalp health and hair thickness. The brand targets consumers seeking scientifically-backed, clean beauty solutions for fuller, healthier hair.

1 investor

Palta provides design and communication services for science-driven companies, helping biotech and innovation firms communicate their research and value to stakeholders. The company partners with companies across multiple sectors including biotech, deeptech, and climate-focused innovators globally.

1 investor

WeCare Bio is a probiotic company serving the probiotic industry with research and development applications. The company has a team of 200+ researchers, primarily at master's level (70%+) and doctoral level (10%).

1 investor

Welgene manufactures and supplies cell culture products for life science research, including specialized media (such as mesenchymal stem cell and keratinocyte media), cell viability assay reagents, ultrapure water, and cell culture plate packages. Its products serve laboratory researchers in biotechnology and molecular biology.

1 investor

Nocturol, Inc. (Wellesley Pharma) is developing a treatment for nocturia, a medical condition in which people are woken frequently at night by the need to urinate. The company targets the hundreds of millions of people who experience multiple nighttime bathroom visits.

1 investor

Wespran develops biotechnology that converts industrial CO2 emissions into valuable chemicals like green methanol using engineered enzymes, serving heavy industries such as refineries and steel plants. The French startup operates a Decarbonization as a Service model to help industrial facilities reduce emissions while generating new revenue.

1 investor

Whelix manufactures autonomous cell-culture systems for research and production, including Associan™, a workcell combining AI-powered liquid handling with integrated incubation and automation for large-scale cell expansion and parallel processing.

1 investor

Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development. The company brings expertise in biotech R&D and commercialization to treat patients using its ADC platform.

1 investor

WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.

1 investor

Microbiome analysis company using lab science and machine learning to identify markers and interventions.

1 investor

Weinnovate Biosolutions develops antimicrobial treatments and infection prevention and control solutions for healthcare providers. The company focuses on reducing hospital-acquired infections and associated hospitalization costs.

1 investor

Wilk is a bio-foodtech company developing cell-cultured milk fat and dairy products, including a hybrid cell-based yogurt made without reliance on animals. It operates in the cultured dairy and cellular agriculture segment of the food industry.

1 investor

Window Therapeutics is a biotechnology company developing therapeutics for cancer and other life-threatening diseases, based on its bottle-brush-analogue-macromonomer (BAM) technology. The company applies molecular chemistry and biology research, originally developed in the MIT laboratory of Dr. Jeremiah Johnson.

1 investor

Winsantor is a clinical-stage biotechnology company developing treatments for peripheral neuropathies, including diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. The company is currently advancing its lead drug candidate, WST-057, through Phase 2 clinical trials in Canada.

1 investor

Wobble Genomics operates an RNA sequencing platform that captures full-length RNA transcripts to identify long RNA biomarkers and novel isoforms for precision medicine. It serves pharmaceutical and diagnostics companies, supporting biomarker discovery, patient stratification, diagnostics, and therapeutic development.

1 investor

WonderTx is an AI-native biotech that develops extrapolative AI models to discover oral drug molecules for targets with validated human biology that currently lack a viable pill-based treatment. The company aims to convert injectable therapies into pills and works on both its own and partner drug discovery programs.

1 investor

Woven Science backs, incubates, and builds companies in the psychedelic and wellness space, operating across drug development, health technology, and plant-medicine product development and distribution. It also runs El Puente, an initiative focused on access and benefit-sharing between psychedelic companies and indigenous peoples.

1 investor

X-Imaging develops laboratory automation systems and collaborative robots for applied chemistry, life sciences, and microbiology research, serving pharmaceutical, biotechnology, and material science laboratories.

1 investor

X-ZELL develops cryoimmunostaining platforms and multiplex panels for cytology laboratories, enabling extraction of multiple biomarkers from single tissue specimens while preserving samples for further testing. The company serves pathologists, oncologists, and diagnostic partners primarily in Southeast Asia with CE-marked, ISO 13485-certified reagents and workflow solutions.

1 investor

未知君 (XBiome) develops microbiome-based therapeutics and diagnostics using AI-driven bioengineering, targeting diseases including cancer immunotherapy, inflammatory conditions, and autism through live bacterial therapeutics and fecal microbiota transplantation (FMT). The company operates in China with clinical development, manufacturing, and computational biology capabilities across multiple cities.

1 investor

Xellia manufactures anti-infective pharmaceutical products with a focus on supply chain continuity and reliable availability of critical active pharmaceutical ingredients in Western markets.

1 investor